calico
10-26-2001, 10:05 AM
Does anyone have any info/insight into this press release? I haven't been able to find anything more informative on the internet. It looks hopeful, but I can't tell if they think it will help with pain from spinal cord/spinal nerve injury.
Calico
CeNeS Begins Clinical Trials To Develop A Better Drug For The Treatment Of Chronic Neuropathic Pain
30/1/2001
Following volunteer studies showing safety and a statistically significant reduction in
perceived pain CeNeS can now begin Phase II trials in neuropathic pain, a large market with few effective treatments.
Targeting a poorly treated population of around 8 million patients suffering from neuropathic pain in the major pharmaceutical markets, CeNeS Pharmaceuticals plc ("CeNeS"; LSE:CEN.L) today
announces start of a Phase II clinical trial for its novel CNS 5161 drug. Chronic neuropathic pain
often affects patients with diabetes, cancer and AIDS.
A Phase I study completed by CeNeS US subsidiary showed that CNS 5161 is safe and well tolerated by human volunteers. Another placebo controlled human volunteer study showed a statistically significant reduction in perceived pain when directly compared with morphine.
CeNeS also announces a strengthening of its intellectual property portfolio in this field following the U.S. Patent and Trademark Office issuance of three patents covering CNS 5161. The patents (Patents Numbers 6147063, 6153604 and 6156741) specifically cover the CNS 5161 drug
molecule, its use to treat neuropathic pain and the composition of analogues to CNS 5161. Each of
these patents will be in force in the United States for 17 years.
Daniel Roach, chief executive of CeNeS Pharmaceuticals plc, comments:
Neuropathic pain is a condition which effects millions of patients and there is no known cure.
Current treatments address the symptoms but only have limited effect - there is a great need
for more effective therapies and the reduction of pain. This Phase II clinical trial of CNS 5161
is a further extension of our strategy to develop a broad portfolio of novel pain control
products and the results will help CeNeS to tailor the administration of this ground breaking
drug and significantly reduce chronic pain in patients.
Notes to Editors:
CeNeS Pharmaceuticals is focused on the discovery, development and the sale of drugs for CNS
disorders and pain control and the development of controlled release drug delivery products in a
range of therapeutic areas. The group has around l30 staff working from modern research and
manufacturing facilities in Cambridge, England, Irvine in Scotland and Boston, USA.
CeNeS has considerable interest in the pain field. It already markets Diconal® and Valoid® for the
treatment of severe pain in the UK and has developed Moraxen®, an innovative formulation of
morphine marketed by Schwarz Pharma in the UK. Moraxen® is also in final stages of development
in Europe and the USA by Bioglan Pharma and Amarin Pharmaceuticals respectively. CeNeS has
also recently licensed Xefo from Nycomed Pharma. Xefo will be launched in the UK in 2001 and is
a novel analgesic for the treatment of post-operative pain.
In its pain development portfolio, in addition to CNS 5161, CeNeS has;
M6G, a metabolite of morphine in Phase II clinical trials for post-operative pain. CEE 04 440, a sublingual formulation of an opioid analgesic to address breakthrough pain in collaboration with Bioglan Pharma, a series of novel peptide drugs in preparation for Phase I clinical trials research programs exploring ion channel modulators in the treatment of pain.
About CNS 5161
CNS 5161 is a potent ion-channel blocker of the NMDA subtype of glutamate receptors. These
receptors have been found to play important roles in pain sensation, particularly in the altered
neuronal states believed to develop in chronic, neuropathic pain syndromes. Pre-clinical studies and clinical trials have demonstrated that by reducing NMDA receptor activity, the excessive
amplification of pain signals that occurs in chronic pain states can be minimised.
About neuropathic pain
Chronic pain often occurs as a result of nerve injuries, such as occur in diabetic neuropathy, shingles (herpes) infections, cancer, surgical trauma and accidental injuries. Neuropathic pain affects about 1.5 million people in the U.S. alone, and can be severely debilitating. Most current pain treatments, such as opiates and anti-inflammatory drugs, are not very effective against neuropathic pain because of the different mechanisms involved, and have undesirable side effects that limit their chronic use
Calico
CeNeS Begins Clinical Trials To Develop A Better Drug For The Treatment Of Chronic Neuropathic Pain
30/1/2001
Following volunteer studies showing safety and a statistically significant reduction in
perceived pain CeNeS can now begin Phase II trials in neuropathic pain, a large market with few effective treatments.
Targeting a poorly treated population of around 8 million patients suffering from neuropathic pain in the major pharmaceutical markets, CeNeS Pharmaceuticals plc ("CeNeS"; LSE:CEN.L) today
announces start of a Phase II clinical trial for its novel CNS 5161 drug. Chronic neuropathic pain
often affects patients with diabetes, cancer and AIDS.
A Phase I study completed by CeNeS US subsidiary showed that CNS 5161 is safe and well tolerated by human volunteers. Another placebo controlled human volunteer study showed a statistically significant reduction in perceived pain when directly compared with morphine.
CeNeS also announces a strengthening of its intellectual property portfolio in this field following the U.S. Patent and Trademark Office issuance of three patents covering CNS 5161. The patents (Patents Numbers 6147063, 6153604 and 6156741) specifically cover the CNS 5161 drug
molecule, its use to treat neuropathic pain and the composition of analogues to CNS 5161. Each of
these patents will be in force in the United States for 17 years.
Daniel Roach, chief executive of CeNeS Pharmaceuticals plc, comments:
Neuropathic pain is a condition which effects millions of patients and there is no known cure.
Current treatments address the symptoms but only have limited effect - there is a great need
for more effective therapies and the reduction of pain. This Phase II clinical trial of CNS 5161
is a further extension of our strategy to develop a broad portfolio of novel pain control
products and the results will help CeNeS to tailor the administration of this ground breaking
drug and significantly reduce chronic pain in patients.
Notes to Editors:
CeNeS Pharmaceuticals is focused on the discovery, development and the sale of drugs for CNS
disorders and pain control and the development of controlled release drug delivery products in a
range of therapeutic areas. The group has around l30 staff working from modern research and
manufacturing facilities in Cambridge, England, Irvine in Scotland and Boston, USA.
CeNeS has considerable interest in the pain field. It already markets Diconal® and Valoid® for the
treatment of severe pain in the UK and has developed Moraxen®, an innovative formulation of
morphine marketed by Schwarz Pharma in the UK. Moraxen® is also in final stages of development
in Europe and the USA by Bioglan Pharma and Amarin Pharmaceuticals respectively. CeNeS has
also recently licensed Xefo from Nycomed Pharma. Xefo will be launched in the UK in 2001 and is
a novel analgesic for the treatment of post-operative pain.
In its pain development portfolio, in addition to CNS 5161, CeNeS has;
M6G, a metabolite of morphine in Phase II clinical trials for post-operative pain. CEE 04 440, a sublingual formulation of an opioid analgesic to address breakthrough pain in collaboration with Bioglan Pharma, a series of novel peptide drugs in preparation for Phase I clinical trials research programs exploring ion channel modulators in the treatment of pain.
About CNS 5161
CNS 5161 is a potent ion-channel blocker of the NMDA subtype of glutamate receptors. These
receptors have been found to play important roles in pain sensation, particularly in the altered
neuronal states believed to develop in chronic, neuropathic pain syndromes. Pre-clinical studies and clinical trials have demonstrated that by reducing NMDA receptor activity, the excessive
amplification of pain signals that occurs in chronic pain states can be minimised.
About neuropathic pain
Chronic pain often occurs as a result of nerve injuries, such as occur in diabetic neuropathy, shingles (herpes) infections, cancer, surgical trauma and accidental injuries. Neuropathic pain affects about 1.5 million people in the U.S. alone, and can be severely debilitating. Most current pain treatments, such as opiates and anti-inflammatory drugs, are not very effective against neuropathic pain because of the different mechanisms involved, and have undesirable side effects that limit their chronic use